Stem-cell firm BioTime said this week that it will open a subsidiary in China called BioTime Asia to expand its stem cell therapeutics and research tools to the Asian market.
BioTime Asia will be based at the Nanshan Memorial Medical Institute, or NSMMI, and will clinically develop and market therapeutic stem cell products in China and market stem cell research products in China and other Asian countries (…)
CordLife, Asia Pacific’s largest network of stem cell banks, on Wednesday launched the most advanced umbilical cord banking technology in the country. The technology has the ability to isolate two cell types that help in hastening the healing process of diabetic foot ulcers.
The patented technology allows access epithelial stem cells that can rejuvenate skin and mucus membranes for treating non-healing wounds as is seen in diabetic ulcer patients, said Steven Fang, group CEO, CordLife. With over 4 crore people in the country diagnosed with diabetes and 1 in every 6 estimated to have an ulcer during the lifetime, CordLife
View Larger Map
China will build Asia’s biggest base to develop uses for stem cell medical technology, which the health minister described as having huge potential for development, a Hong Kong newspaper reported on Wednesday.
Stem cell techniques use the body’s master cells to create new cells that medical researchers hope can be used to fight diseases and heal injuries. Chinese Health Minister Chen Zhu said his country could become a leader in finding uses for the technology.
“The stem cell and regenerative medicine sector is one of China’s new high-tech biological sectors with the strongest development potential,” Chen said in a
International Stem Cell Corporation announced that its Research and Development team has advanced its program to create a functional and transplantable human cornea by developing a new method to derive corneal endothelium-like cells from human pluripotent stem cells.
This work represents a significant step towards the creation of complete cornea tissue that can be used for transplantation and supports prior data showing indications of corneal endothelium generated by ISCO’s collaborators at Sankara Nethralaya Eye Hospital, India. Such cells by themselves may potentially promote wound healing and regeneration of the cornea and therefore could be used as a standalone medical treatment.
Image via Wikipedia
China will build Asia’s largest stem cell technology laboratory in its push to increase its stake in the competitive sector.
Health Minister Chen Zhu said there was huge potential for China to grow in this new field, it was reported.
Stem cell technology uses master cells in the body to create new cells. Medical researchers hope these new cells can be used to fight diseases and heal injuries.
“The stem cell and regenerative medicine sector is one of China’s new high-tech biological sectors with the strongest development potential,” Chen said during the launch of the project in eastern Jiangsu province